Hims & Hers shares fall after revenue miss and Q1 loss
Hims & Hers posted a surprise loss as it shifted to branded GLP-1 drugs. Shares fell 10 percent even as the firm raised its annual revenue forecast for 2026.
X24 PerspectiveRelated Assets:
X24 Perspective